Philips, GE look to Saudi Arabian healthcare market; Navidea tries again for FDA approval;

 @FierceMedDev: Boston Sci snagged EU approval for its new stent with bioabsorbable coating. News | Follow @FierceMedDev

 @MarkHFierce: Fidelity is investing $75M into Trivitron Healthcare, an Indian company focused on imaging and lab Dx. Release | Follow @MarkHFierce

 @DamianFierce: The latest Cleveland Clinic top 10 innovations list includes some novel medical devices. Article | Follow @DamianFierce

> Cardiovascular Systems ($CSII) say its fiscal 2013 revenue hit $23.5 million, a 25% jump fueled by sales of it lead medical device to treat peripheral artery disease. Net losses reached $5.2 million, up from a $3.9 million net loss over the same period last year, driven by higher clinical trial and marketing spending. Release

> Philips and General Electric are among medical device or medical equipment companies investing in Saudi Arabia, Bloomberg reports. They anticipate major growth there, with health spending poised to reach $20 billion by 2016 as diabetes, heart disease and cancer rates soar. Story

> On the rebound from an earlier rejection, Navidea Biopharmaceuticals is re-filing its FDA application for Lymphoseek, a cancer diagnostic tool. News

> Thermedical gained 510(k) clearance in the U.S. to start marketing new technology that enables coagulation and ablation of soft tissue during percutaneous, laparoscopic and intraoperative surgical procedures. Item

> Chinese medical device giant Mindray Medical ($MR) will take part in MEDICA 2012, a global medical trade fair planned from Nov. 14-17 in Dusseldorf, Germany. Release

> CE mark in hand, Blue Medical is launching its Protégé NC drug-eluting balloon around the world. Release

> Beijing's Dehaier Medical inked a $1 million contract to provide medical devices to China's XinJiang Province. More

Biotech News

 @FierceBiotech: Ipsen braces for $153M write-off as troubled biotech partner declares bankruptcy. News | Follow @FierceBiotech

 @JohnCFierce: Biocon (India) scouts R&D pact after GE unit grabs stake in research division. Story | Follow @JohnCFierce

 @RyanMFierce: Biotech's boneyard: 2012 report on the dead, dying, disabled (and some reborn) biotech operations. Happy Halloween! Special Report | Follow @RyanMFierce

> Researchers nab $11M to fund second look at AstraZeneca's stockpile of failed drugs. Article

> Biogen streak lives on with upbeat PhIII results for hemophilia A therapy. Story

Pharma News

@FiercePharma: BMJ says no more clinical trial publications if actual data isn't open for outside review. More | Follow @FiercePharma

> Novo hikes forecast on 62% jump in Victoza sales. News

> BMJ editor flogs Roche for Tamiflu data secrecy. Story

> Novartis building new plant as pipeline fills with biologics. Article

Drug Delivery News

> Twice-yearly opioid dependence implant steps closer to the market. Item

> Ocular Therapeutix eyes up positive results for OTX-TP2. Article

> Starpharma technology delivers 40-fold more docetaxel to tumor. Report

> Paclitaxel particles extend life threefold in mouse bladder cancer. News

Biomarkers News

> Seeing is believing: Biomarkers visible to the naked eye. Item

> Blood biomarker tags NeuVax's role in breast cancer treatment. Article

> Marking glimpses of activity for Lilly's Alzheimer drug after PhIII struggles. Report

> U.K. researchers spot new marker for prostate cancer prognosis. News

> Chromosome cap length predicts pancreatic cancer risk. Story

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.